Summary

The cancer diagnostics market is projected to reach USD 44.92 billion by 2031 from USD 29.86 billion in 2026, registering a CAGR of 7.0%.

Cancer diagnostics play a critical role in oncology by enabling early detection, accurate diagnosis, disease characterization, treatment selection, and ongoing monitoring of cancer. The cancer diagnostics market, segmented by product, comprises a broad portfolio of instruments and consumables used across in vitro diagnostics (IVD), anatomic pathology, and imaging-based diagnostics. Market growth is driven by the increasing adoption of advanced diagnostic technologies, sustained demand for consumables, rising global cancer incidence, expanding screening initiatives, and growing diagnostic testing volumes.
The market encompasses a wide range of diagnostic technologies, including PCR, immunohistochemistry (IHC), in situ hybridization (ISH), next-generation sequencing (NGS), microarrays, flow cytometry, immunoassays, histopathology, biopsy, CT, MRI, PET, mammography, and ultrasound. These technologies are used to diagnose both solid tumors and hematological malignancies, supporting applications such as cancer screening, early detection, disease diagnosis and characterization, treatment decision-making, and disease monitoring, including recurrence detection.

Based on product, the cancer diagnostics market is segmented into IVD testing, anatomic pathology, and imaging-based diagnostics. Among these, IVD testing accounted for the largest market share and is projected to witness the fastest growth during the forecast period. The segment's dominance is driven by the increasing global burden of cancer, growing emphasis on early detection and precision oncology, rising adoption of liquid biopsy and molecular diagnostic technologies, and expanding use of biomarker-based testing for cancer screening, diagnosis, treatment selection, and disease monitoring. Continuous advancements in next-generation sequencing (NGS), polymerase chain reaction (PCR), immunoassays, companion diagnostics, and AI-enabled diagnostic platforms have significantly enhanced diagnostic accuracy, sensitivity, and turnaround time. Supported by increasing healthcare investments, favorable reimbursement for molecular testing, government-led cancer screening initiatives, and expanding access to personalized medicine, the IVD testing segment is expected to maintain its leading position in the global cancer diagnostics market throughout the forecast period.

Based on end user, the cancer diagnostics market is segmented into hospitals and clinical laboratories. Among these, hospitals account for the largest market share due to their high patient volumes, comprehensive diagnostic infrastructure, and ability to provide integrated cancer care encompassing screening, diagnosis, treatment planning, and disease monitoring under a single setting. Hospitals are the primary centers for advanced imaging, biopsy procedures, molecular testing, and multidisciplinary oncology care, driving significant demand for cancer diagnostic services. The increasing adoption of precision oncology, companion diagnostics, next-generation sequencing (NGS), and AI-enabled diagnostic workflows, coupled with rising investments in hospital-based cancer centers and expanding access to advanced diagnostic technologies, continues to strengthen the dominance of the hospital segment. Furthermore, growing government initiatives for cancer screening, increasing cancer admissions, and the integration of digital pathology and laboratory information systems are reinforcing the leading position of hospitals in the global cancer diagnostics market, while clinical laboratories continue to witness steady growth driven by increasing outsourcing of specialized molecular and genomic testing.

Based on region, the cancer diagnostics market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. North America accounted for the largest market share in 2025 and continues to serve as the primary market driver, supported by its advanced healthcare infrastructure, high healthcare expenditure, favorable reimbursement policies, and early adoption of innovative cancer diagnostic technologies. The region has a high prevalence of cancer, well-established screening programs, and increasing demand for early detection and precision oncology, resulting in the widespread adoption of molecular diagnostics, next-generation sequencing (NGS), liquid biopsy, companion diagnostics, digital pathology, and advanced imaging technologies across hospitals, cancer centers, and clinical laboratories. The strong presence of leading diagnostics companies, continuous technological advancements, substantial investments in oncology research, supportive regulatory frameworks, and expanding integration of artificial intelligence into cancer diagnostics further reinforce North America's market leadership.
A breakdown of the primary respondents (supply-side) for the cancer diagnostics market referred to in this report is provided below:
・ By Company Type: Tier 1: 40%, Tier 2: 30%, and Tier 3: 30%
・ By Designation: C-level: 55%, Director Level: 27%, and Others: 18%
・ By Region: North America: 43%, Europe: 28%, Asia Pacific: 20%, Latin America: 6% and Middle East & Africa: 3%
Prominent players in the cancer diagnostics market include Roche Diagnostics (Switzerland), Danaher Corporation (US), Thermo Fisher Scientific Inc. (US), Abbott Laboratories (US), Siemens Healthineers AG (Germany), Agilent Technologies, Inc. (US), QIAGEN N.V. (Netherlands), Illumina, Inc. (US), Hologic, Inc. (US), Becton, Dickinson and Company (US), Exact Sciences Corporation (US), Guardant Health, Inc. (US), Sysmex Corporation (Japan), Foundation Medicine, Inc. (US), Myriad Genetics, Inc. (US), NeoGenomics Laboratories, Inc. (US), bioMérieux SA (France), and Revvity, Inc. (US), among others.
Research Coverage
The report evaluates the cancer diagnostics market and estimates the market size and future growth potential of this market based on various segments, including product, end user, and region. The report also includes a competitive analysis of the major players in this market, along with company profiles, product offerings, recent developments, and key market strategies.
Reasons to Buy the Report
The report will assist market leaders and new entrants in the cancer diagnostics s market with data on the nearest approximations of revenue figures for the overall market and its subsegments. The report will help stakeholders understand the competitive landscape and gain insights into better positioning their businesses and developing effective go-to-market strategies. It also enables stakeholders to understand market dynamics and provides insights into key drivers, restraints, challenges, and growth opportunities influencing the cancer diagnostics market.
This report provides insights into the following points:
・Analysis of Key Drivers (Increasing global burden of cancer driven by aging populations, lifestyle changes, and environmental risk factors; Growing emphasis on early cancer detection and screening to improve patient outcomes and survival rates; Advancements in molecular diagnostics, next-generation sequencing (NGS), liquid biopsy, and companion diagnostics enabling precision oncology; Rising adoption of AI-powered imaging and digital pathology solutions to enhance diagnostic accuracy and workflow efficiency; Increasing investments in cancer research, biomarker discovery, and personalized medicine), restraints (High cost of advanced diagnostic technologies and genomic testing; Limited accessibility to sophisticated diagnostic infrastructure in low- and middle-income countries; Stringent regulatory approval and reimbursement challenges; Complexity in interpreting genomic and molecular data requiring specialized expertise), opportunities (Growing demand for non-invasive diagnostic techniques such as liquid biopsy; Expansion of national cancer screening programs and awareness initiatives; Increasing adoption of precision medicine and companion diagnostics; Rising investments in AI-enabled diagnostics, digital pathology, and multi-cancer early detection (MCED) tests; Growing healthcare infrastructure and diagnostic capabilities in emerging markets), and challenges (Shortage of skilled oncology and pathology professionals; Data privacy, interoperability, and integration issues with digital diagnostic platforms; High validation requirements for novel biomarkers and diagnostic assays; Reimbursement variability across different healthcare systems; Ensuring equitable access to advanced cancer diagnostics while maintaining affordability and diagnostic accuracy).
・Product Enhancement/Innovation: Comprehensive details about product launches and anticipated trends in the cancer diagnostics market.
・Market Development: Thorough knowledge and analysis of the profitable rising markets by product, type, application, technology, end user, and region.
・Market Diversification: Comprehensive information about newly launched products, expanding markets, current advancements, and investments in the cancer diagnostics market.
・Competitive Assessment: Thorough evaluation of the market shares, growth plans, offerings, and capacities of the major competitors in the cancer diagnostics market.

ページTOPに戻る

Table of Contents

1 INTRODUCTION 55
1.1 STUDY OBJECTIVES 55
1.2 MARKET DEFINITION 55
1.3 STUDY SCOPE 56
1.3.1 MARKETS COVERED AND REGIONAL SCOPE 56
1.3.2 INCLUSIONS AND EXCLUSIONS 57
1.3.3 YEARS CONSIDERED 59
1.4 CURRENCY CONSIDERED 59
1.5 STAKEHOLDERS 59
1.6 SUMMARY OF CHANGES 60
2 EXECUTIVE SUMMARY 61
2.1 KEY INSIGHTS AND MARKET HIGHLIGHTS 61
2.2 KEY MARKET PARTICIPANTS: SHARE INSIGHTS AND STRATEGIC DEVELOPMENTS 62
2.3 DISRUPTIVE TRENDS SHAPING MARKET 63
2.4 HIGH-GROWTH SEGMENTS AND EMERGING FRONTIERS 64
2.5 SNAPSHOT: GLOBAL MARKET SIZE, GROWTH RATE, AND FORECAST 65
3 PREMIUM INSIGHTS 66
3.1 CANCER DIAGNOSTICS MARKET OVERVIEW 66
3.2 ASIA PACIFIC CANCER DIAGNOSTICS MARKET, BY COUNTRY AND TECHNOLOGY 67
3.3 CANCER DIAGNOSTICS MARKET: GEOGRAPHIC GROWTH (2026−2031) 68
4 MARKET OVERVIEW 69
4.1 INTRODUCTION 69
4.2 MARKET DYNAMICS 69
4.2.1 DRIVERS 70
4.2.1.1 Growing incidence of cancer 70
4.2.1.2 Growth in number of private diagnostics centers 71
4.2.1.3 Availability of favorable reimbursement policies 72
4.2.2 RESTRAINTS 72
4.2.2.1 High capital investment requirements 72
4.2.2.2 High cost of advanced diagnostic imaging systems 72
4.2.3 OPPORTUNITIES 73
4.2.3.1 Increasing adoption of companion diagnostics 73
4.2.3.2 Expansion of organized cancer screening programs 73
4.2.3.3 Growing demand for cancer diagnostics in emerging markets 73
4.2.4 CHALLENGES 73
4.2.4.1 Increasing adoption of refurbished diagnostic imaging systems 73
4.2.4.2 Shortage of skilled professionals 73
4.2.4.3 Limited healthcare infrastructure and low awareness in developing countries 74
4.2.4.4 Product recalls and diagnostic test failures 74
4.3 UNMET NEEDS AND WHITE SPACES 74
4.3.1 UNMET NEEDS IN CANCER DIAGNOSTICS MARKET 74
4.3.2 WHITE SPACE OPPORTUNITIES 74
4.4 INTERCONNECTED MARKETS AND CROSS-SECTOR OPPORTUNITIES 75
4.4.1 INTERCONNECTED MARKETS 75
4.5 STRATEGIC MOVES BY TIER 1/2/3 PLAYERS 76
4.5.1 KEY MOVES AND STRATEGIC FOCUS 76
5 INDUSTRY TRENDS 77
5.1 PORTER’S FIVE FORCES ANALYSIS 77
5.1.1 BARGAINING POWER OF SUPPLIERS 78
5.1.2 BARGAINING POWER OF BUYERS 78
5.1.3 THREAT OF NEW ENTRANTS 78
5.1.4 THREAT OF SUBSTITUTES 78
5.1.5 INTENSITY OF COMPETITIVE RIVALRY 78
5.2 MACROECONOMIC INDICATORS 78
5.2.1 INTRODUCTION 78
5.2.2 GDP TRENDS AND FORECAST 79
5.3 SUPPLY CHAIN ANALYSIS 81
5.4 ECOSYSTEM ANALYSIS 82
5.5 INVESTMENT AND FUNDING SCENARIO 83
5.6 PRICING ANALYSIS 84
5.6.1 AVERAGE SELLING PRICE BY PRODUCT 84
5.6.2 AVERAGE SELLING PRICE OF GLUCOSE MONITORING TEST STRIPS, BY KEY PLAYER 84
5.6.3 AVERAGE SELLING PRICE, BY REGION 85
5.6.3.1 Average selling price of glucose monitoring test strips, by region 85
5.6.3.2 Average selling price of infectious disease testing products, by region 85
5.6.3.3 Average selling price of cardiometabolic monitoring products, by region 86
5.7 VALUE CHAIN ANALYSIS 87
5.8 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS 88
5.9 CASE STUDY ANALYSIS 89
5.9.1 PRICE IMPACT ANALYSIS 90
5.9.2 IMPACT ON REGION 90
5.9.2.1 North America 90
5.9.2.2 Europe 90
5.9.2.3 Asia Pacific 90
6 TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, PATENTS, INNOVATIONS, AND FUTURE APPLICATIONS 91
6.1 KEY EMERGING TECHNOLOGIES 91
6.1.1 IVD TESTING 91
6.1.2 COMPLEMENTARY TECHNOLOGIES 91
6.1.2.1 Molecular diagnostics 91
6.1.3 ADJACENT TECHNOLOGIES 91
6.1.3.1 Biochemical technologies 91
6.2 TECHNOLOGY/PRODUCT ROADMAP 92
6.3 PATENT ANALYSIS 93
6.3.1 LIST OF MAJOR PATENTS 94
6.4 FUTURE APPLICATIONS 94
6.5 IMPACT OF AI/GENERATIVE AI ON CANCER DIAGNOSTICS MARKET 94
6.5.1 INTRODUCTION 94
6.5.2 TOP USE CASES AND MARKET POTENTIAL 95
6.5.3 KEY COMPANIES IMPLEMENTING AI 95
6.5.4 FUTURE OF AI 96
7 REGULATORY LANDSCAPE AND SUSTAINABILITY 97
7.1 REGIONAL REGULATIONS AND COMPLIANCE 97
7.1.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 97
7.1.2 INDUSTRY STANDARDS 99
7.2 SUSTAINABILITY INITIATIVES 100
7.2.1 ENVIRONMENTAL IMPACT AND ECO-FRIENDLY INITIATIVES IN CANCER DIAGNOSTICS 100
7.2.1.1 Eco-friendly Initiatives 100
7.3 SUSTAINABILITY IMPACT AND REGULATORY POLICY INITIATIVES 101
8 CUSTOMER LANDSCAPE & BUYER BEHAVIOR 102
8.1 DECISION-MAKING PROCESS 102
8.2 BUYER STAKEHOLDERS AND BUYING EVALUATION CRITERIA 102
8.2.1 KEY STAKEHOLDERS IN BUYING PROCESS 102
8.2.2 BUYING CRITERIA 103
8.3 ADOPTION BARRIERS & INTERNAL CHALLENGES 103
8.4 UNMET NEEDS OF VARIOUS END USERS 105
8.5 MARKET PROFITABILITY 105
8.5.1 REVENUE POTENTIAL 105
8.5.2 COST DYNAMICS 106
8.5.3 MARGIN OPPORTUNITIES IN KEY APPLICATIONS 106
9 CANCER DIAGNOSTICS MARKET, BY APPLICATION 107
9.1 INTRODUCTION 108
9.2 SCREENING & EARLY DETECTION 108
9.2.1 INCREASING EMPHASIS ON EARLY CANCER DETECTION TO DRIVE SEGMENT 108
9.3 DIAGNOSIS & DISEASE CHARACTERIZATION 111
9.3.1 GOVERNMENT INITIATIVES TO EXPAND HEALTHCARE ACCESS TO DRIVE SEGMENT 111
9.4 TREATMENT DECISION SUPPORT 113
9.4.1 RISING DEMAND FOR PRECISION ONCOLOGY TO PROPEL SEGMENT 113
9.5 TREATMENT MONITORING & DISEASE PROGRESSION ASSESSMENT 116
9.5.1 INCREASING DEMAND FOR DETECTION OF DISEASE PROGRESSION SUPPORT SEGMENT GROWTH 116
9.6 POST-TREATMENT SURVEILLANCE & RECURRENCE DETECTION 118
9.6.1 GROWING EMPHASIS ON POST-TREATMENT MONITORING TO DRIVE SEGMENT 118
10 CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY 122
10.1 INTRODUCTION 123
10.2 IVD TESTING 123
10.2.1 POLYMERASE CHAIN REACTION 126
10.2.1.1 PCR-based diagnostic tests preferred as they provide simple representations of genomic data 126
10.2.2 IN SITU HYBRIDIZATION 129
10.2.2.1 ISH used for identification of specific mRNA species within sample cells 129
10.2.3 IMMUNOHISTOCHEMISTRY 131
10.2.3.1 Increasing use of IHC tests for cancer diagnostics to boost market growth 131
10.2.4 NEXT-GENERATION SEQUENCING 135
10.2.4.1 NGS dominates IVD testing market 135
10.2.5 IMMUNOASSAY 137
10.2.5.1 Immunoassay segment accounted for second-largest share of cancer diagnostics market for IVD testing 137
10.2.6 MICROARRAY 140
10.2.6.1 Cost-effectiveness of microarray technology to support market growth 140
10.2.7 FLOW CYTOMETRY 142
10.2.7.1 Limited budgets restrain segment growth 142
10.2.8 OTHER IVD TECHNOLOGIES 145
10.3 IMAGING TECHNOLOGIES 148
10.3.1 MAGNETIC RESONANCE IMAGING 150
10.3.1.1 Technological advancements to boost segment growth 150
10.3.2 COMPUTED TOMOGRAPHY 153
10.3.2.1 CT is widely used technique in cancer diagnostics 153
10.3.3 POSITRON EMISSION TOMOGRAPHY (PET) 155
10.3.3.1 Widely used nuclear imaging technique in cancer diagnostics 155
10.3.4 MAMMOGRAPHY 158
10.3.4.1 Increasing government initiatives for breast cancer screening to drive segment growth 158
10.3.5 ULTRASOUND 160
10.3.5.1 Substantial clinical advancements and technical innovations to support market growth 160
10.4 ANATOMIC PATHOLOGY 163
10.4.1 INTRODUCTION 163
10.4.1.1 Histopathology 166
10.4.1.1.1 Growing demand for high-throughput, error-free staining to drive market 166
10.4.1.2 Cytopathology 169
10.4.1.2.1 Rising cervical cancer screening volumes to boost demand for automated cytology systems 169
10.5 BIOPSIES 172
11 CANCER DIAGNOSTICS MARKET, BY TYPE 175
11.1 INTRODUCTION 176
11.2 SOLID TUMORS 176
11.3 BREAST CANCER 179
11.3.1 SEGMENT TO ACCOUNT FOR LARGEST SHARE DURING FORECAST PERIOD 179
11.4 LUNG CANCER 182
11.4.1 LUNG CANCER SEGMENT ACCOUNTED FOR THE SECOND-LARGEST SHARE 182
11.5 COLORECTAL CANCER 185
11.5.1 INCREASING INCIDENCE OF COLORECTAL CANCER TO DRIVE MARKET GROWTH 185
11.6 GASTRIC CANCER 187
11.6.1 SEGMENT GROWTH SUPPORTED BY INCREASING ADOPTION OF BIOMARKER-BASED TESTING FOR TREATMENT SELECTION 187
11.7 HEAD & NECK CANCER 190
11.7.1 SEGMENT TO BE DRIVEN BY INCREASING AGING POPULATION 190
11.8 PROSTATE CANCER 193
11.8.1 RISING GLOBAL DISEASE BURDEN AND EVOLVING DIAGNOSTIC LANDSCAPE TO BOOST SEGMENT 193
11.9 CERVICAL CANCER 196
11.9.1 INCREASE IN SCREENING, HPV TESTING, AND BIOMARKER ADOPTION TO DRIVE MARKET GROWTH 196
11.10 MELANOMA 199
11.10.1 INCREASING INCIDENCE OF MELANOMA TO DRIVE MARKET GROWTH 199
11.10.2 OTHER SOLID TUMORS 202
11.11 LIQUID TUMORS 204
11.12 LEUKEMIA 207
11.12.1 SEGMENT CONTINUES TO REPRESENT SIGNIFICANT SHARE OF GLOBAL HEMATOLOGIC (LIQUID) CANCER BURDEN 207
11.13 MYELOMA 210
11.13.1 RISING CASES, PARTICULARLY ACROSS ASIA AND AFRICA, TO DRIVE MARKET 210
11.14 LYMPHOMA 213
11.14.1 INCREASING DISEASE BURDEN TO DRIVE SEGMENT 213
12 CANCER DIAGNOSTICS MARKET, BY PRODUCT 217
12.1 INTRODUCTION 218
12.2 IVD TESTING 218
12.2.1 KITS & REAGENTS 221
12.2.1.1 Increasing adoption due to ease of use to boost segment 221
12.2.2 INSTRUMENTS 224
12.2.2.1 PCR instruments 227
12.2.2.1.1 Cost-effectiveness drives growth of segment 227
12.2.2.2 NGS instruments 229
12.2.2.2.1 NGS is an emerging technology for cancer diagnostics 229
12.2.2.3 Microarrays 232
12.2.2.3.1 Use in determination of primary sites in metastatic carcinomas to boost market 232
12.2.3 IN SITU HYBRIDIZATION 234
12.2.3.1 Use for identification of specific mRNA species within sample cells – key driver 234
12.2.4 IMMUNOHISTOCHEMISTRY 237
12.2.4.1 Increasing use of IHC tests for cancer diagnostics to boost market growth 237
12.2.5 IMMUNOASSAY 240
12.2.5.1 Segment holds second-largest share of cancer diagnostics market for IVD testing 240
12.2.6 FLOW CYTOMETRY 242
12.2.6.1 Use across diagnosis, monitoring, and treatment to propel market 242
12.2.7 OTHER IVD TESTING INSTRUMENTS 245
12.3 ANATOMIC PATHOLOGY 247
12.3.1 INTRODUCTION 247
12.3.2 INSTRUMENTS 251
12.3.2.1 Slide staining systems 251
12.3.2.1.1 Increasing focus on automation to drive market 251
12.3.2.2 Tissue processing systems 254
12.3.2.2.1 Use in automatic processing of tissue samples to boost market 254
12.3.2.3 Cell processors 257
12.3.2.3.1 Used to remove unwanted matter from cytology samples 257
12.3.2.4 Microtomes 259
12.3.2.4.1 Segment gaining traction as rising biopsy volumes and automation drive demand 259
12.3.2.5 Embedding systems 261
12.3.2.5.1 Automated tissue embedding gains momentum in cancer diagnostics 261
12.3.2.6 Cover slippers 264
12.3.2.6.1 Automated cover slippers strengthen workflow efficiency in cancer diagnostics 264
12.3.2.7 Digital pathology scanners 266
12.3.2.7.1 Shift toward automated cancer diagnostics to accelerate segment growth 266
12.3.2.8 Other anatomic pathology instruments 269
12.3.3 CONSUMABLES 271
12.3.3.1 Antibodies 274
12.3.3.1.1 Cancer diagnostic consumables market 274
12.3.3.2 Kits & Reagents 276
12.3.3.2.1 Use of kits is increasing among end users owing to their ease of use 276
12.3.3.3 Probes 279
12.3.3.3.1 Probes Enable Precise Molecular Detection in Cancer Diagnostics 279
12.3.3.4 Other consumables 282
12.4 IMAGING-BASED 284
12.4.1 INSTRUMENTS 284
12.4.1.1 CT systems 287
12.4.1.1.1 Technological advancements to drive growth of segment 287
12.4.1.2 Ultrasound systems 290
12.4.1.2.1 Increasing incidence of cancer to drive segment growth 290
12.4.2 MRI SYSTEMS 292
12.4.2.1 Rising cancer incidence and growing adoption of MRI drive market growth 292
12.4.2.2 Mammography systems 295
12.4.2.2.1 Increasing incidence of breast cancer to drive growth of segment 295
12.4.2.3 PET-CT 297
12.4.2.3.1 Technological advancements in nuclear imaging systems to drive segment 297
12.4.3 CONSUMABLES 299
12.4.3.1 Contrast agents 299
12.4.3.1.1 Increasing incidence of cancer to drive segment 299
12.4.3.2 Radiopharmaceuticals 304
12.4.3.2.1 Increasing availability of radioisotopes to drive segment 304
13 CANCER DIAGNOSTICS MARKET, BY END USER 308
13.1 INTRODUCTION 309
13.2 HOSPITALS & CLINICS 309
13.2.1 SEGMENT IS LARGEST END USER OF CANCER DIAGNOSTIC PRODUCTS 309
13.3 DIAGNOSTIC LABORATORIES 312
13.3.1 INCREASING INCIDENCE OF CANCER TO DRIVE GROWTH 312
14 CANCER DIAGNOSTICS MARKET, BY REGION 315
14.1 INTRODUCTION 316
14.2 NORTH AMERICA 317
14.2.1 US 325
14.2.1.1 Expected to be dominant in North American market 325
14.2.2 CANADA 333
14.2.2.1 High cancer burden, aging population, and expanding screening programs to support market growth 333
14.3 EUROPE 341
14.3.1 GERMANY 350
14.3.1.1 Availability of reimbursements for colorectal cancer screening to drive market growth 350
14.3.2 UK 359
14.3.2.1 Favorable government initiatives to drive market growth 359
14.3.3 FRANCE 368
14.3.3.1 Increasing government funding for cancer diagnosis and prevention to support market growth 368
14.3.4 ITALY 378
14.3.4.1 High incidence of cancer to support market growth 378
14.3.5 SPAIN 386
14.3.5.1 High incidence of chronic diseases to drive market growth 386
14.3.6 REST OF EUROPE 395
14.4 ASIA PACIFIC 404
14.4.1 CHINA 413
14.4.1.1 Increasing healthcare expenditure to drive market growth 413
14.4.2 JAPAN 422
14.4.2.1 Advanced healthcare infrastructure to support market growth 422
14.4.3 INDIA 431
14.4.3.1 Expanding healthcare sector in country to drive market growth 431
14.4.4 SOUTH KOREA 440
14.4.4.1 Focus on genomic research and precision medicine to boost market growth 440
14.4.5 AUSTRALIA 448
14.4.6 REST OF ASIA PACIFIC 456
14.4.7 LATIN AMERICA 465
14.4.7.1 Increasing number of cancer screening programs to support market growth 465
14.4.8 BRAZIL 475
14.4.8.1 Expansion of cancer screening programs to support market growth 475
14.4.9 MEXICO 484
14.4.9.1 Increasing cancer screening initiatives and diagnostic infrastructure to drive market growth 484
14.4.10 REST OF LATIN AMERICA 494
14.4.11 MIDDLE EAST & AFRICA 502
14.4.11.1 Increasing incidence of cancer to drive market growth 502
15 COMPETITIVE LANDSCAPE 512
15.1 INTRODUCTION 512
15.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 512
15.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN CANCER DIAGNOSTICS MARKET 512
15.3 REVENUE ANALYSIS, 2023–2025 513
15.4 MARKET SHARE ANALYSIS, 2025 514
15.5 COMPANY VALUATION AND FINANCIAL METRICS 515
15.6 BRAND/PRODUCT COMPARISON 516
15.6.1 ABBOTT 516
15.6.2 F. HOFFMANN-LA ROCHE LTD. 517
15.6.3 DANAHER 517
15.7 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2025 517
15.7.1 STARS 517
15.7.2 EMERGING LEADERS 518
15.7.3 PERVASIVE PLAYERS 518
15.7.4 PARTICIPANTS 518
15.7.5 COMPANY FOOTPRINT, KEY PLAYERS, 2025 519
15.7.5.1 Company footprint 519
15.7.5.2 Region footprint 519
15.7.5.3 End user footprint 520
15.7.5.4 Product footprint 521
15.7.5.5 Technology footprint 521
15.8 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023 522
15.8.1 PROGRESSIVE COMPANIES 522
15.8.2 RESPONSIVE COMPANIES 522
15.8.3 DYNAMIC COMPANIES 522
15.8.4 STARTING BLOCKS 522
15.9 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025 523
15.9.1 DETAILED LIST OF KEY STARTUPS/SMES 523
15.9.2 COMPETITIVE BENCHMARKING OF STARTUPS/SMES 524
15.10 COMPETITIVE SCENARIO 525
15.10.1 PRODUCT LAUNCHES AND APPROVALS 525
16 COMPAMY PROFILE 526
16.1 KEY PLAYERS 526
16.1.1 F. HOFFMANN-LA ROCHE 526
16.1.1.1 Business overview 526
16.1.1.2 Products offered 527
16.1.1.3 Recent developments 528
16.1.1.3.1 Product launches and approvals 528
16.1.1.3.2 Deals 528
16.1.1.3.3 Expansions 529
16.1.1.4 MnM view 529
16.1.1.4.1 Right to win 529
16.1.1.4.2 Strategic choices 529
16.1.1.4.3 Weaknesses and competitive threats 529
16.1.2 DANAHER CORPORATION 530
16.1.2.1 Business overview 530
16.1.2.2 Products offered 531
16.1.2.3 Recent developments 532
16.1.2.3.1 Product launches and approvals 532
16.1.2.3.2 Deals 532
16.1.2.4 MnM view 533
16.1.2.4.1 Right to win 533
16.1.2.4.2 Strategic choices 533
16.1.2.4.3 Weaknesses and competitive threats 533
16.1.3 THERMO FISHER SCIENTIFIC INC 534
16.1.3.1 Business overview 534
16.1.3.2 Products offered 535
16.1.3.3 Recent developments 536
16.1.3.3.1 Product launches and approvals 536
16.1.3.3.2 Deals 536
16.1.3.4 MnM view 536
16.1.3.4.1 Right to win 536
16.1.3.4.2 Strategic choices 536
16.1.3.4.3 Weaknesses and competitive threats 537
16.1.4 ABBOTT LABORATORIES 538
16.1.4.1 Business overview 538
16.1.4.2 Products offered 539
16.1.4.3 Recent developments 540
16.1.4.3.1 Deals 540
16.1.4.3.2 Expansions 540
16.1.4.4 MnM view 540
16.1.4.4.1 Right to win 540
16.1.4.4.2 Strategic choices 540
16.1.4.4.3 Weaknesses and competitive threats 540
16.1.5 AGILENT TECHNOLOGIES INC. 541
16.1.5.1 Business overview 541
16.1.5.2 Products offered 542
16.1.5.3 Recent developments 543
16.1.5.3.1 Product launches and approvals 543
16.1.5.3.2 Deals 543
16.1.5.3.3 Expansions 544
16.1.5.4 MnM view 544
16.1.5.4.1 Right to win 544
16.1.5.4.2 Strategic choices 544
16.1.5.4.3 Weaknesses and competitive threats 544
16.1.6 QIAGEN N.V. 545
16.1.6.1 Business overview 545
16.1.6.2 Products offered 546
16.1.6.3 Recent developments 547
16.1.6.3.1 Product launches and approvals 547
16.1.6.3.2 Deals 547
16.1.6.3.3 Expansions 547
16.1.6.4 MnM view 548
16.1.6.4.1 Right to win 548
16.1.6.4.2 Strategic choices 548
16.1.6.4.3 Weaknesses and competitive threats 548
16.1.7 ILLUMINA, INC 549
16.1.7.1 Business overview 549
16.1.7.2 Products offered 550
16.1.7.3 Recent developments 551
16.1.7.3.1 Product launches and approvals 551
16.1.7.3.2 Deals 551
16.1.7.3.3 Expansions 552
16.1.7.4 MnM view 552
16.1.7.4.1 Right to win 552
16.1.7.4.2 Strategic choices 552
16.1.7.4.3 Weaknesses and competitive threats 552
16.1.8 HOLOGIC, INC 553
16.1.8.1 Business overview 553
16.1.8.2 Products offered 554
16.1.8.3 Recent developments 555
16.1.8.3.1 Product launches and approvals 555
16.1.8.3.2 Deals 556
16.1.8.3.3 Expansions 556
16.1.8.4 MnM view 556
16.1.8.4.1 Right to win 556
16.1.8.4.2 Strategic choices 557
16.1.8.4.3 Weaknesses and competitive threats 557
16.1.9 BECTON, DICKINSON AND COMPANY 558
16.1.9.1 Business overview 558
16.1.9.2 Products offered 559
16.1.9.3 Recent developments 560
16.1.9.3.1 Product launches and approvals 560
16.1.9.3.2 Deals 560
16.1.9.4 MnM view 560
16.1.9.4.1 Right to win 560
16.1.9.4.2 Strategic choices 561
16.1.9.4.3 Weaknesses and competitive threats 561
16.1.10 SIEMENS HEALTHINEERS AG 562
16.1.10.1 Business overview 562
16.1.10.2 Products offered 563
16.1.10.3 Recent developments 564
16.1.10.3.1 Product launches and approvals 564
16.1.10.3.2 Expansions 564
16.1.10.4 MnM view 564
16.1.10.4.1 Right to win 564
16.1.10.4.2 Strategic choices 565
16.1.10.4.3 Weaknesses and competitive threats 565
16.1.11 EXACT SCIENCES CORPORATION 566
16.1.11.1 Business overview 566
16.1.11.2 Products offered 567
16.1.11.3 Recent developments 568
16.1.11.3.1 Product launches and approvals 568
16.1.11.3.2 Deals 568
16.1.11.3.3 Expansions 568
16.1.12 GUARDANT HEALTH, INC 569
16.1.12.1 Business overview 569
16.1.12.2 Products offered 570
16.1.12.3 Recent developments 571
16.1.12.3.1 Product launches and approvals 571
16.1.12.3.2 Deals 571
16.1.13 SYSMEX CORPORATION 572
16.1.13.1 Business overview 572
16.1.13.2 Products offered 573
16.1.13.3 Recent developments 574
16.1.13.3.1 Expansions 574
16.1.14 BIOMÉRIEUX SA. 575
16.1.14.1 Business overview 575
16.1.14.2 Products offered 576
16.1.14.3 Recent developments 577
16.1.14.3.1 Product launches and approvals 577
16.1.15 MYRIAD GENETICS, INC 578
16.1.15.1 Business overview 578
16.1.15.2 Products offered 579
16.1.15.3 Recent developments 580
16.1.15.3.1 Product launches and approvals 580
16.1.15.3.2 Deals 580
16.2 OTHER PLAYERS 581
16.2.1 NEOGENOMICS, INC 581
16.2.2 NATERA, INC 582
16.2.3 TEMPUS AI, INC 582
16.2.4 GRAIL, INC 583
16.2.5 CARIS LIFE SCIENCES, INC, INC. 583
16.2.6 PERSONALIS, INC 584
16.2.7 DELFI DIAGNOSTICS, INC 584
16.2.8 FULGENT GENETICS, INC 585
16.2.9 BURNING ROCK BIOTECH LIMITED 586
16.2.10 GENETRON HOLDINGS LIMITED 587
17 RESEARCH METHODOLOGY 588
17.1 RESEARCH DATA 588
17.2 RESEARCH APPROACH 588
17.2.1 SECONDARY RESEARCH 588
17.2.1.1 Key data from secondary sources 589
17.2.2 PRIMARY DATA 590
17.2.2.1 Primary sources 590
17.2.2.2 Key data from primary sources 591
17.2.2.3 Key industry insights 592
17.3 MARKET SIZE ESTIMATION 593
17.3.1 BOTTOM-UP APPROACH 594
17.3.1.1 Approach 1: Company revenue estimation approach 594
17.3.1.2 Approach 2: Presentations of companies and primary interviews 594
17.3.1.3 Growth forecast 595
17.3.2 TOP-DOWN APPROACH 596
17.4 MARKET BREAKDOWN AND DATA TRIANGULATION 597
17.5 MARKET SHARE ANALYSIS 598
17.6 RESEARCH ASSUMPTIONS 598
17.6.1 PARAMETRIC ASSUMPTIONS 598
17.6.2 GROWTH RATE ASSUMPTIONS 598
17.7 RESEARCH LIMITATIONS 599
17.8 RISK ASSESSMENT 599
18 APPENDIX 600
18.1 DISCUSSION GUIDE 600
18.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 606
18.3 CUSTOMIZATION OPTIONS 608
18.4 RELATED REPORTS 608
18.5 AUTHOR DETAILS 609